Pages that link to "Q54680864"

The following pages link to The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. (Q54680864):

Displaying 28 items.

• Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. (Q34233555) (← links)
• Myasthenia gravis: an update for the clinician (Q34377145) (← links)
• Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development (Q34612356) (← links)
• Voltage gated calcium channel antibody-related neurological diseases (Q35179343) (← links)
• Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy (Q35239122) (← links)
• Treatment of myasthenia gravis based on its immunopathogenesis (Q35675970) (← links)
• Myasthenia gravis: a clinical-immunological update (Q36783864) (← links)
• The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma (Q37054967) (← links)
• Rituximab therapy in pemphigus and other autoantibody-mediated diseases (Q37620483) (← links)
• Current and emerging treatments for the management of myasthenia gravis (Q37918361) (← links)
• Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. (Q37968620) (← links)
• Treatment strategies for myasthenia gravis: an update (Q38024858) (← links)
• Treatment in Lambert-Eaton myasthenic syndrome (Q38070758) (← links)
• Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management (Q38183705) (← links)
• Myasthenia gravis: subgroup classification and therapeutic strategies (Q38588012) (← links)
• Rituximab treatment of myasthenia gravis: A systematic review (Q39121466) (← links)
• Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome (Q43716462) (← links)
• Paraneoplastic neurological syndromes: general treatment overview (Q44922918) (← links)
• Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. (Q46009832) (← links)
• Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. (Q47980248) (← links)
• Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis. (Q48142572) (← links)
• Clinical features and evolution of juvenile myasthenia gravis in a French cohort (Q50213611) (← links)
• Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients (Q50912480) (← links)
• Treatment options in paraneoplastic disorders of the peripheral nervous system. (Q51838886) (← links)
• Lambert-Eaton Myasthenic Syndrome. (Q53073843) (← links)
• Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia. (Q53118752) (← links)
• Management challenges in muscle-specific tyrosine kinase myasthenia gravis. (Q54464610) (← links)
• Lambert-Eaton Myasthenic syndrome: early diagnosis is key. (Q64893535) (← links)